Introduction
============

In the last century, the population aged over 60 years old has rapidly increased around the world ([@B9]). Aging is the major risk factor for many chronic diseases such as cancer, diabetes, hypertension, and neurodegenerative disorders ([@B56]). In particular, aging has been correlated with the occurrence of several types of dementia, affecting 5--10% of people over 65, and about 50% of people over 85 years old according to the Alzheimer's Disease (AD) International ([@B73]). AD, the most common and still incurable form of dementia, shares several similar cellular alterations with brain aging including mitochondrial dysfunction, oxidative stress, Ca^2+^ dysregulation, and impaired proteostasis ([@B63]; [@B57]; [@B79]; [@B69]). Most cases of AD are sporadic (SAD) and characterized by a late onset of symptoms, such as a decline of intellectual and cognitive functions and irreversible memory loss as major features. Several genes have been found to increase the risk of SAD, with the gene for apolipoprotein E (APOE) being the most studied, specifically, the polymorphism that produces the 𝜀4 allele of the APOE, APOE4 variant of the protein ([@B1]). In addition, nearly 1% of the cases of AD that are dominantly inherited present an early development known as familial AD (FAD) characterized by mutations in presenilin-1 (PS1) and -2 (PS2) or in the amyloid precursor protein (APP; [@B86]). Both SAD and FAD are characterized by neuronal cell death and assumed to be similar to some extent ([@B45]), but the key events prior to cell death are still unclear.

Mitochondria are central organelles in neuronal physiology integrating several crucial functions such as cell respiration, energy metabolism, Ca^2+^ homeostasis, and reactive oxygen species (ROS) generation, all of which have been found to be dysregulated in aging, AD, and other neurodegenerative disorders such as Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD) disease ([@B101]; [@B84]; [@B53]; [@B67]). Here we present an overview of selected findings regarding mitochondrial dysfunction in neurodegenerative disease and discuss their potential as therapeutic targets.

Er-Mitochondria Communication and Ca^2+^ Regulation in Age-Associated Neurodegenerative Diseases
================================================================================================

Communication between organelles allows cells to function and adapt in a changing cellular environment. The endoplasmic reticulum (ER) and mitochondria couple at specific sites termed mitochondria-associated membranes (MAMs), which integrate and coordinate several cellular functions, including synthesis and exchange of phospholipid, apoptosis, mitochondrial dynamics, and Ca^2+^ signaling ([@B65]; **Figure [1A](#F1){ref-type="fig"}**). Remarkably, all these processes are affected early during aging, AD pathogenesis, and other neurodegenerative conditions, suggesting a role for MAMs in the pathogenesis of these diseases ([@B24]; [@B48]; [@B36]; [@B4]). For example, the overexpression of both wild-type and familial ALS/FTD mutant TDP-43 in HEK293, CV-1, and NSC34 cell lines reduces ER--mitochondria associations and Ca^2+^ exchange between these two organelles ([@B90]; **Figure [1C](#F1){ref-type="fig"}**). Likewise, loss of Sigma 1 receptor (which is responsible for some familial forms of ALS/FTD) has been shown to interfere with ER--mitochondria associations ([@B10]; **Figure [1C](#F1){ref-type="fig"}**). Conversely, an increase in the lipidic enzymatic function of MAMs and their inter-organelle extension has been described in fibroblasts from patients with SAD, in human SAD brains, and in AD mouse models ([@B6]; [@B48]). Remarkably, one of the most common and validated risk factors for SAD, the presence of APOE4 ([@B50]), has recently been associated with an increase in the ER--mitochondrial communication and MAM enzymatic activity ([@B92]; **Figure [1B](#F1){ref-type="fig"}**). Furthermore, MAMs are highly enriched in PS1 and PS2 proteins ([@B5]) which when mutated, as in fibroblasts from patients with FAD, also increase the lipidic enzymatic function of the MAMs and ER--mitochondria communication ([@B6]), through a mechanism that involves an interaction between the mutated form of PS2 and mitofusin-2 (Mfn2; **Figure [1B](#F1){ref-type="fig"}**), a key protein in the formation of MAMs ([@B34]).

![Endoplasmic reticulum and mitochondria interactions under different scenarios. **(A)** Endoplasmic reticulum--mitochondrial interaction at a proper distance allows a correct transfer of calcium to the mitochondrial matrix to sustain bioenergetic function. **(B)** Shortening of the distance at the endoplasmic reticulum--mitochondrial interaction, or an increase in either the mitochondrial calcium uptake or the calcium release from the endoplasmic reticulum, causes an exaggerated transfer of calcium to mitochondria affecting its normal bioenergetic function that leads to cell death. **(C)** Separation of the endoplasmic reticulum and mitochondria causes a decrease in the calcium transfer to the mitochondrial matrix generating a drop in the bioenergetic and metabolic activity of the mitochondria.](fnins-12-00470-g001){#F1}

Conditions that increase or decrease the extension of MAMs will affect the transfer of Ca^2+^ from the ER to mitochondria, resulting in either a mitochondrial Ca^2+^ overload, or a lack of Ca^2+^. If the transfer of Ca^2+^ is excessive, cell death occurs ([@B83]). If Ca^2+^ transfer to mitochondria is too low, a bioenergetics crisis occurs, also resulting in cell death ([@B16]). Importantly, Ca^2+^ is dysregulated in the aged brain and in AD ([@B61]; [@B38]; [@B58]). Upregulation of Ca^2+^ levels can both initiate and accelerate several AD features, from amyloid deposition to synapse loss ([@B91]). Several mechanisms have been proposed to explain the upregulation of cytoplasmic Ca^2+^ levels in AD including overexpression of the ryanodine receptor (RyR; [@B19]), or β-amyloid (Aβ)-triggering release of Ca^2+^ from both extracellular and intracellular sources ([@B25]). Another mechanism involves an increase of Ca^2+^ leak from the ER through sensitization of the inositol 1,4,5-trisphosphate receptor (InsP~3~R) Ca^2+^ channel by directed interaction with FAD-linked PS mutants ([@B22], [@B23]) or indirectly by interaction of FAD-linked PS mutants with the SERCA pump ([@B42]). In agreement with the latter, it has been demonstrated that overexpression of the FAD-linked PS2 mutant leads to an increase in the generation of cytosolic Ca^2+^ hot spots, ER--mitochondria tethering, and mitochondrial Ca^2+^ uptake ([@B103]). This in turn may result in mitochondrial Ca^2+^ overload and could explain the metabolic dysfunction and cell death observed in AD (**Figure [1B](#F1){ref-type="fig"}**). On the other hand, decreasing intracellular Ca^2+^ overload, specifically through a reduction of the InsP~3~R protein expression by 50%, normalizes FAD PS-associated Ca^2+^ signaling and rescues the biochemical, electrophysiological, and behavioral phenotypes observed in two different PS1-FAD animal models ([@B87]; **Figure [1B](#F1){ref-type="fig"}**). Altogether, the above findings highlight the importance of MAMs and the transfer of Ca^2+^ from the ER to mitochondria in AD pathogenesis and their potential as a therapeutic target.

The role of MAMs in aging has just begun to be unveiled. Similar to what has been observed in AD models, aging increases the ER to mitochondria Ca^2+^ transfer in long-term culture of hippocampal neurons, with correlates with an increase of the mitochondrial Ca^2+^ uniporter (MCU; [@B15]; **Figure [1B](#F1){ref-type="fig"}**). Interestingly, a decrease in Ca^2+^ transfer to mitochondria and a dissociation of the MAMs have been described in cardiomyocytes from old mice suggesting that the type of modification that MAMs undergo with aging might be cell specific ([@B32]).

The Mitochondrial Permeability Transition Pore (Mptp) Formation in Age-Associated Neurodegenerative Diseases
============================================================================================================

Under conditions of Ca^2+^ and/or ROS overload, formation of the mitochondrial permeability transition pore (mPTP) takes place, which corresponds to a non-selective channel formed by a protein complex spanning the outer and inner mitochondrial membranes ([@B11]). In physiological conditions, transient opening of the mPTP can regulate Ca^2+^ levels in the mitochondrial matrix ([@B52]). However, dysregulated mPTP opening triggers the release of most matrix metabolites such as ROS, Ca^2+^, and NAD ^+^, leading to loss of the mitochondrial membrane potential, inhibition of oxidative phosphorylation (OXPHOS), and mitochondrial swelling ([@B31]; [@B80]). Even though several proteins are known to participate in mPTP formation \[anion channel VDAC, adenine nucleotide translocator (ANT), mitochondrial ATP synthase (F0F1), phosphate carrier (PiC), and cyclophilin D (CypD; [@B11]; [@B77]), its detailed structural configuration is not yet entirely known.

The mPTP has been linked to neurodegeneration *in vitro* and *in vivo*. In neural progenitor cells, Aβ-amyloid exposure leads to mPTP opening and a decrease in mitochondrial membrane potential, release of cytochrome C, and cell death ([@B51]). In human AD brains, Aβ-amyloid binds CypD in mitochondria ([@B29]), and CypD deficiency improves mitochondrial function, memory, and learning in an AD mouse model ([@B27]). Aβ-induced neurotoxicity *in vitro* was also attenuated pharmacologically by inhibition of the mPTP using cyclosporine A (CsA) on neural stem cells ([@B21]). Interestingly, it has been shown that CypD knock-out mice exhibit delayed axonal degeneration, a common feature of diverse neurodegenerative diseases ([@B8]; [@B18]; [@B81]). Indeed, genetic deletion of CypD delays disease progression in other mouse models of neurodegenerative disorders, including ALS ([@B68]), PD ([@B93]), and multiple sclerosis ([@B35]). Therefore, novel compounds that inhibit mPTP opening are currently been developed, including sanglifehrin A, N-Me-Ala-6-cyclosporin A, and antmanide ([@B77]).

Aging also modifies the opening probability of the mPTP ([@B80]). During aging, the probability of the mPTP opening increases due to higher expression levels of CypD and the CypD-activator p53 ([@B72]). Furthermore, the expression of HSP90, a chaperone that binds CypD to trigger its degradation, is decreased in aged cells ([@B60]), which could also increase the mPTP opening probability. This evidence is further supported by a faster Ca^2+^-induced mitochondrial swelling in purified liver mitochondria obtained from aged mice ([@B41]). Interestingly, CypD is inactivated by the deacetylase SIRT3 ([@B44]), a known modulator of longevity in diverse species ([@B54]). The reported decline in SIRT3 activity during aging ([@B13]) may lead to a greater activation of the mPTP, underscoring the role of mitochondria in longevity and onset of age-dependent neurodegenerative diseases. Interestingly, several modulators of longevity, including metformin, mitochondrial UPR, and caloric restriction inhibit the activation of the mPTP ([@B12]; [@B2]; [@B3]), and may contribute to lifespan extension ([@B80]). A key role for mitochondria in age-related disorders has been associated to broad damaging events including increased ROS production and defects in the regulation of intracellular Ca^2+^ levels, which are directly associated to mPTP activation with profound negative consequences for cell survival. Therefore, mPTP emerges as a potential target for neuroprotection in age-related neurodegenerative conditions.

Mitochondria, Ros, Aging, and Neurodegeneration
===============================================

Reactive oxygen species are chemical species that are produced by most cell types. The group of molecules that fulfill the criteria for ROS includes hydrogen peroxide, and the highly reactive species superoxide anion and hydroxyl radical ([@B100]). The production of ROS in cells is controlled by enzymatic or non-enzymatic mechanisms. The main source for ROS production in terms of quantitative production is the mitochondria ([@B49]). Mitochondria produces superoxide anion, a by-product of the inefficient transfer of electrons by the electron transport chain (ETC) during OXPHOS, that is quickly converted into hydrogen peroxide by the action of the superoxide dismutases 1--3 (SOD1--3; [@B74]). Of note, despite mitochondria being the main source of ROS in cells, hydrogen peroxide can be produced by more than 30 different enzymes ([@B39]).

While a huge amount of work in the past focused on the deleterious roles for ROS species in cells and organisms, including the "free radical" or "oxidative stress" theory of aging ([@B46]) supported by many studies ([@B47]; [@B14]; [@B40]), there is growing evidence in the last decades that ROS may serve physiological functions ([@B104]; [@B88]; [@B100]). Related to aging, other studies show that unbalanced ROS production does not modify lifespan in mice under tightly controlled conditions ([@B94]; [@B76]). Moreover, it was demonstrated that there is no increased oxidative damage with age ([@B7]; [@B55]). Currently, it has been proposed that adaptive or hormetic production of ROS is required to maintain several cellular mechanisms including stem cell proliferation and fate determination in the brain ([@B85]; [@B20]).

In terms of neurodegeneration associated to aging, it has been reported in AD that the Aβ peptide interacts with the mitochondrial protein termed amyloid binding alcohol dehydrogenase (ABAD) in AD mouse models and in post-mortem samples derived from AD human patients. The functional consequence of such an interaction is an increase in ROS production due to abnormal mitochondrial membrane permeability ([@B66]). Altered OXPHOS increases the generation of ROS ([@B59]) and is indeed a hallmark for early AD abnormalities in humans. In fact, samples from human subjects show that mitochondrial-encoded OXPHOS genes are altered in aging, mild cognitive impairment, and AD ([@B70]). Similarly, AD mouse models have shown that both Aβ and tau protein can induce alterations in mitochondrial proteins involved in OXPHOS ([@B17]; [@B78]; [@B30]), causing an aberrant ROS generation leading to cellular damage. In addition, ROS are known to cause mitochondrial fragmentation ([@B97]), which reduces mitochondrial performance ([@B98]) favoring the generation of more ROS and cellular damage associated to it.

Mitochondrial Dysfunction and Synaptic Deficits
===============================================

Synapses are neuronal structures in which mitochondria are fundamental ([@B64]) by providing large amounts of ATP required to fuel synaptic vesicle physiology and by acting as a Ca^2+^ buffer modulating cytoplasmic Ca^2+^ signal and hence, neurotransmission ([@B37]; [@B95]; [@B43]; [@B96]). Synaptic mitochondria are more vulnerable to cumulative damage showing impaired Ca^2+^ uptake capacity and increased propensity to undergo mPTP compared to non-synaptic mitochondria ([@B82]). Likewise, in an APP/PS1 AD mouse, synaptic mitochondrial function was significantly more affected than non-synaptic mitochondria ([@B26]). Synaptic deficit is an early event in the pathogenesis of several neurodegenerative disorders including AD and worsens with disease progression and age ([@B99]). The extent of cognitive decline in AD patients is tightly associated with the extent of synapse loss in specific brain regions including cortex and hippocampus ([@B82]; [@B71]). Post-mortem hippocampus from AD patients shows a considerable decrease in dendritic spine density ([@B33]) and transgenic mouse models of AD show age-dependent reduction in spine density before plaque deposition ([@B62]). Along these lines, in aged synapses and from AD models, a decline in mitochondrial respiration and signs of mitochondrial damage such as reduced antioxidant contents and increased oxidative stress markers has been described ([@B28]; [@B75]). Proteomic analysis of aged synaptic mitochondria reveals changes in ETC proteins, antioxidants, and proteins related to mitochondrial dynamics ([@B89]). Just recently, through the use of cytoplasmic hybrid ("cybrid") technology, [@B102] were able to recapitulate mitochondrial structural and functional changes observed in AD-affected brains. In this model, their findings demonstrate that AD-affected mitochondria elicited detrimental effects on synaptic development ([@B102]). How ER vesicles found in the synaptic region and the transfer of Ca^2+^ contribute to the impairment of mitochondria and synaptic formation remains to be explored, but given the dysregulation of Ca^2+^ observed during aging, AD, and other neurodegeneration, an important role is expected. Elucidating the factors that underlie early synaptic dysfunction will be key to prevent the widespread neurodegeneration associated with aging.

Conclusion
==========

Aging continues to be the most relevant risk factor for AD, the most common form of dementia in the elderly, and other neurodegenerative diseases. Both aging and neurodegeneration are accompanied by a loss in the ability of the cells to adjust and rewire their metabolic networks to keep a tight balance between energy production and expenditure in an ever-changing environment. Mitochondria work as an adaptable metabolic control, a "rheostat," that integrates inputs from the intra and extracellular environment to generate functional outputs that adjust cell behavior and energy production and consumption. Several lines of evidence suggest that mitochondrial function deteriorates with increasing age and the progression of several neurodegenerative diseases. This supports the notion that aging and the neurodegenerative diseases such as AD may share a common root, the failure of the rheostat program. Since Ca^2+^ is also altered in both conditions and can either energize or overload the rheostat depending on the concentration, understanding how MAM formation is regulated is important. Identifying the players that participate in the regulation to assure a proper Ca^2+^ transfer to mitochondria is critical in order to determine the real potential of this intracellular signaling platform as an intervention candidate to improve aging and hinder the onset of neurodegenerative disease such as AD.
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